There are disparities in access to innovative therapies and entries into clinical trials, but FDA's recent proposed guidance could help close gaps, said John W. Sweetenham, MD, senior director of clinical affairs and executive medical director, Huntsman Cancer Institute at the University of Utah.
There are disparities in access to innovative therapies and entries into clinical trials, but FDA's recent proposed guidance could help close gaps, said John W. Sweetenham, MD, senior director of clinical affairs and executive medical director, Huntsman Cancer Institute at the University of Utah.
Transcript
There are large disparities in cancer care delivery and outcomes — what can be done to address these disparities and close the gap by ensuring members of minority or underserved communities have access to care and are well educated about their care?
At the moment it’s very clear that access to most innovative therapies is a source of disparity. Entry into clinical trials, there are disparities there and those disparities go beyond the ones that we normally think about, ethnic and racial minorities, but into areas such as rural populations and their access to care. In terms of how we iron those out, I think that’s a massive subject and it’s partly educational, it’s partly more robust funding systems and honestly I think it’s partly electronic. I think the solution to these largely are going to require more sophisticated software platforms for communicating with the patients than we have right now.
Do you think the FDA’s proposed guidance documents for improving access to clinical trials will close the gaps?
I think to some extent they will. I think access to clinical trials probably has improved in recent years. I think the likelihood is that it will continue to improve but I think there are so many issues that we don’t fully cover — culturally sensitive and culturally competent kind of information about studies, understanding the different cultural challenges that there are towards clinical trials in, for example, some populations that don’t have a word for cancer in their vocabulary, and there are some. And so I think that some of these educational challenges that we have are the really big ones, but I think the new guidance will be helpful.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More